Zacks Investment Research lowered shares of U.S. Physical Therapy (NYSE:USPH) from a buy rating to a hold rating in a research report released on Friday.
According to Zacks, “U.S. Physical Therapy, Inc. is the largest publicly-traded, pure-play operator of outpatient physical and occupational therapy clinics. The clinics provide pre- and post-operative care for a variety of orthopedic-related disorders and sports-related injuries, rehabilitation of injured workers and preventative care. USPh also manages several physical therapy facilities for third parties, including physician groups. Each of USPh’s clinics are directed by a licensed physical therapist that drive patient volume via local physicians, former patients and other referral sources. Marketing representatives are used to further augment sales. Historically, USPh has grown its business through de novo development; approximately two-thirds of USPh clinics were originally start-ups. Strategic acquisitions, which accelerate the Company’s growth, are structured like the de novo partnerships, with significant ownership retained by founders. “
Several other equities research analysts have also recently weighed in on the stock. Cantor Fitzgerald reiterated a buy rating and set a $80.00 price objective on shares of U.S. Physical Therapy in a research report on Tuesday, January 9th. Jefferies Group set a $76.00 target price on shares of U.S. Physical Therapy and gave the stock a hold rating in a research note on Friday, February 23rd. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. U.S. Physical Therapy currently has a consensus rating of Hold and a consensus target price of $79.40.
U.S. Physical Therapy (NYSE:USPH) last posted its quarterly earnings data on Thursday, March 8th. The company reported $0.49 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.49. U.S. Physical Therapy had a net margin of 5.38% and a return on equity of 13.12%. The company had revenue of $109.20 million during the quarter, compared to analysts’ expectations of $104.12 million. research analysts anticipate that U.S. Physical Therapy will post 2.39 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Friday, April 13th. Investors of record on Wednesday, March 21st will be paid a dividend of $0.23 per share. The ex-dividend date is Tuesday, March 20th. This is a positive change from U.S. Physical Therapy’s previous quarterly dividend of $0.20. This represents a $0.92 annualized dividend and a yield of 1.06%. U.S. Physical Therapy’s dividend payout ratio is currently 45.71%.
In other U.S. Physical Therapy news, Director Mark J. Brookner sold 2,625 shares of the firm’s stock in a transaction on Wednesday, December 27th. The shares were sold at an average price of $71.23, for a total value of $186,978.75. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Lawrance W. Mcafee sold 2,000 shares of the firm’s stock in a transaction on Tuesday, December 12th. The shares were sold at an average price of $72.56, for a total transaction of $145,120.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 8,875 shares of company stock worth $637,971. 3.10% of the stock is owned by insiders.
Institutional investors have recently added to or reduced their stakes in the business. Rhumbline Advisers lifted its stake in shares of U.S. Physical Therapy by 15.8% in the third quarter. Rhumbline Advisers now owns 40,729 shares of the company’s stock valued at $2,503,000 after buying an additional 5,570 shares in the last quarter. Copeland Capital Management LLC bought a new position in shares of U.S. Physical Therapy in the fourth quarter valued at $12,459,000. BNP Paribas Arbitrage SA lifted its stake in shares of U.S. Physical Therapy by 57.1% in the third quarter. BNP Paribas Arbitrage SA now owns 6,452 shares of the company’s stock valued at $396,000 after buying an additional 2,346 shares in the last quarter. King Luther Capital Management Corp lifted its stake in shares of U.S. Physical Therapy by 61.3% in the third quarter. King Luther Capital Management Corp now owns 57,695 shares of the company’s stock valued at $3,545,000 after buying an additional 21,935 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. lifted its stake in shares of U.S. Physical Therapy by 5.4% in the third quarter. Schwab Charles Investment Management Inc. now owns 56,510 shares of the company’s stock valued at $3,473,000 after buying an additional 2,873 shares in the last quarter. 96.53% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This piece was reported by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The original version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3256655/zacks-investment-research-downgrades-u-s-physical-therapy-usph-to-hold.html.
About U.S. Physical Therapy
U.S. Physical Therapy, Inc, through its subsidiaries, operates outpatient physical therapy clinics that provide pre-and post-operative care, and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers and neurological-related injuries.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for U.S. Physical Therapy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for U.S. Physical Therapy and related companies with MarketBeat.com's FREE daily email newsletter.